Actively Recruiting
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Led by University of Nebraska · Updated on 2025-12-15
126
Participants Needed
1
Research Sites
331 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
CONDITIONS
Official Title
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 60 years or older
- Diagnosis of a hematological malignancy or other serious hematological disorder requiring allogeneic hematopoietic cell transplantation
- Planned to receive any reduced-intensity conditioning regimen with an HLA-matched donor at loci A, B, C, and DRB1
- Karnofsky Performance Status of 70% or higher
You will not qualify if you...
- Previous history of one or more prior allogeneic stem cell transplants
- Planned use of high-dose cyclophosphamide (approximately 50 mg/kg or more) as part of conditioning prior to transplant
- Known liver cirrhosis or advanced liver disease impacting cyclophosphamide metabolism
- Diagnosis of myelofibrosis
- Creatinine clearance less than 40 mL/min/1.73 m2
- Systolic cardiac dysfunction with ejection fraction less than 45%
- Use of haploidentical or mismatched donor
- Any condition increasing risk of toxicities with post-transplant cyclophosphamide as judged by physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
Research Team
T
Taylor Johnson
CONTACT
I
IIT OFFICE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here